Skip to main content


Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro

Fig. 4

HIV induction of activation markers in vivo. Experimental mice were separated into four groups: control, HIV-infected, HIV-infected treated with low-dose baricitinib (10 mg/kg), and HIV-infected treated with high-dose baricitinib (50 mg/kg). Mice were sacrificed 14 days after infection, and brain samples were homogenized and assessed for encephalitis markers and viral protein using flow cytometry. a CD45/MHCII double staining as mononuclear phagocyte activation markers. b Activated p24+ human macrophages. c Activated astrocytes. **p < 0.001

Back to article page